Adrenocortical insufficiency Medical Services in China

Adrenocortical insufficiency (AI) is a potentially life-threatening endocrine disorder characterized by inadequate production of adrenal corticosteroids—primarily cortisol and, in some cases, aldosterone—by the adrenal cortex. It is classified into primary (Addison’s disease), secondary (due to pituitary ACTH deficiency), and tertiary (due to hypothalamic CRH deficiency) forms. Primary AI results from direct adrenal gland damage—most commonly autoimmune adrenalitis (accounting for ~80% of cases in high-income countries), but also infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic malignancy, or genetic disorders (e.g., congenital adrenal hyperplasia, adrenoleukodystrophy). Secondary and tertiary AI arise from impaired stimulation of the adrenal glands due to pituitary or hypothalamic dysfunction, often triggered by prolonged exogenous glucocorticoid therapy, pituitary tumors, surgery, radiation, or infiltrative diseases. Epidemiologically, primary AI affects approximately 100–140 per million people globally, with an annual incidence of 4–6 per million; it occurs equally across sexes and peaks in the 30–50 age range. Secondary AI is significantly more common—especially among patients with chronic glucocorticoid use—and its true prevalence is likely underreported. Key risk factors include prior autoimmune conditions (e.g., type 1 diabetes, thyroiditis, vitiligo), long-term systemic corticosteroid treatment (>3 weeks at ≥5 mg prednisone equivalent/day), pituitary/hypothalamic pathology, critical illness with adrenal involvement, and genetic predisposition (e.g., AIRE gene mutations in APS-1). Untreated or poorly managed AI profoundly impairs quality of life: patients frequently experience debilitating fatigue, orthostatic dizziness, unintentional weight loss, gastrointestinal distress (nausea, vomiting, abdominal pain), salt craving, hypoglycemia, depression, brain fog, and reduced physical stamina. Acute adrenal crisis—a medical emergency marked by hypotension, shock, hyponatremia, hyperkalemia, and altered mental status—carries a mortality rate of 6–25% if not promptly treated. Even in stable chronic management, patients report limitations in work capacity, social engagement, and emotional resilience due to fear of crisis, medication adherence burden, and unpredictable symptom flares during stressors (e.g., infection, injury, surgery). Lifelong hormone replacement (glucocorticoids ± mineralocorticoids), patient education on sick-day rules, and regular endocrinology follow-up are essential to mitigate morbidity and restore functional well-being.

Adrenocortical insufficiency (AI), also known as adrenal insufficiency, is a potentially life-threatening endocrine disorder characterized by inadequate production of cortisol—and often aldosterone—by the adrenal cortex. It may be primary (Addison’s disease, due to adrenal gland destruction), secondary (pituitary ACTH deficiency), or tertiary (hypothalamic CRH deficiency). Prompt diagnosis and lifelong, individualized glucocorticoid and mineralocorticoid replacement are essential to prevent adrenal crisis, chronic morbidity, and mortality.

Conservative treatment forms the cornerstone of AI management and emphasizes non-pharmacologic strategies integrated with pharmacotherapy. Patients require comprehensive education on sick-day rules: doubling or tripling oral hydrocortisone doses during intercurrent illness (e.g., fever, infection, injury), increasing doses before elective procedures, and recognizing early signs of adrenal crisis (profound fatigue, nausea, hypotension, abdominal pain, confusion). Stress-dosing protocols must be personalized based on age, weight, comorbidities, and clinical context. Dietary sodium supplementation (3–6 g/day) is advised for patients with primary AI, especially in hot climates or during physical exertion, to counteract mineralocorticoid deficiency. Regular monitoring of blood pressure, electrolytes (sodium, potassium), fasting glucose, and bone mineral density is mandatory to detect complications such as hyponatremia, hyperkalemia, osteoporosis, or iatrogenic Cushingoid features. Lifestyle counseling includes avoidance of abrupt glucocorticoid withdrawal, emphasis on consistent sleep-wake cycles to support circadian cortisol rhythm, and psychological support to address anxiety related to crisis risk and chronic disease burden.

Pharmacologic therapy is lifelong and hormone-replacement—not suppressive—in nature. For glucocorticoid replacement, hydrocortisone remains the gold-standard agent due to its short half-life (8–12 hours) and physiologic cortisol-like activity. Typical adult dosing is 15–25 mg/day, administered in two or three divided doses: ~50% upon waking, ~25% at noon, and ~25% in late afternoon (avoiding evening dosing to minimize HPA axis suppression and insomnia). Prednisone (3–5 mg/day) or dexamethasone (0.25–0.75 mg/day) may be used in select cases but lack circadian fidelity and carry higher risks of metabolic and bone toxicity; thus, they are generally discouraged except when adherence to multiple daily doses is problematic and closely supervised. Mineralocorticoid replacement with fludrocortisone acetate (0.05–0.2 mg once daily) is mandatory in primary AI to restore sodium retention, intravascular volume, and renin-angiotensin-aldosterone system homeostasis. Dose titration is guided by upright plasma renin activity (target: upper third of normal range), serum potassium (3.5–4.5 mmol/L), and absence of orthostatic hypotension. In secondary/tertiary AI, fludrocortisone is typically unnecessary unless confirmed hypoaldosteronism exists. Emergency injectable glucocorticoids (e.g., hydrocortisone sodium succinate 100 mg IV/IM) must be prescribed and patients trained in self-administration; medical alert identification is strongly recommended.

Surgical treatment plays no role in routine AI management, as the condition is hormonal—not structural—in origin. However, surgery becomes relevant in specific etiologies: bilateral adrenalectomy is indicated for severe, refractory Cushing’s syndrome causing secondary AI; resection of ACTH-secreting pituitary adenomas (transsphenoidal surgery) may restore HPA axis function in select cases of secondary AI; and removal of metastatic or infectious adrenal masses (e.g., tuberculosis, fungal abscesses) may preserve residual adrenal tissue if diagnosed early. Importantly, surgical intervention does not cure AI—it may even precipitate or exacerbate it—and must always be followed by rigorous perioperative stress-dosing and long-term replacement. Adrenalectomy for incidentaloma-related subclinical AI is contraindicated; observation and functional testing are preferred.

Treatment advantages in China reflect robust integration of traditional and modern endocrinology infrastructure. Major academic hospitals (e.g., PUMCH, Ruijin Hospital, West China Hospital) offer multidisciplinary AI clinics with endocrinologists, clinical pharmacists, nutritionists, and psychologists—all fluent in standardized Chinese Adrenal Insufficiency Management Guidelines (2022 edition). Access to affordable generic hydrocortisone and fludrocortisone is widespread via the National Reimbursement Drug List, reducing financial barriers. Advanced diagnostics—including high-sensitivity ACTH assays, salivary cortisol profiling, and dynamic corticotropin stimulation tests—are available in over 200 certified endocrine laboratories nationwide. Telemedicine platforms (e.g., WeDoctor, Ping An Good Doctor) enable remote dose titration support and crisis triage, particularly beneficial for rural patients. Moreover, China’s national AI patient registry facilitates longitudinal outcome tracking and evidence generation tailored to East Asian phenotypes, revealing lower average hydrocortisone requirements (15–20 mg/day) and higher prevalence of autoimmune polyglandular syndrome type 2 compared with Western cohorts—informing more precise, population-specific dosing.

Recovery and long-term wellness hinge on proactive self-management and structured follow-up. Patients should schedule endocrinology visits every 3–6 months initially, then annually if stable, with assessment of symptom control, medication adherence, growth (in children), body composition, and quality-of-life metrics (e.g., Addison’s Disease Health Questionnaire). Annual dual-energy X-ray absorptiometry (DXA) scanning is recommended for those on >5 mg prednisone-equivalent daily for >3 months. Vaccination against influenza, pneumococcus, and COVID-19 is critical, given increased infection-related crisis risk. Women of childbearing age require preconception counseling: hydrocortisone doses often increase by 20–50% in the third trimester, and vaginal delivery necessitates stress-dosing (hydrocortisone 100 mg IV at labor onset, then 50 mg every 8 hours until 24 hours postpartum). Finally, psychosocial resilience is cultivated through peer support networks (e.g., China Adrenal Alliance), mindfulness-based stress reduction programs endorsed by the Chinese Endocrine Society, and routine screening for depression and adrenal fatigue misconceptions—ensuring care remains biopsychosocially grounded, evidence-based, and patient-centered.